Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4652 Clinical response to somatostatin analogues in patients with DIPNECH: Findings from a new longitudinal registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) often presents with symptoms of cough and dyspnoea. DIPNECH remains understudied, and response to somatostatin analogues (SSAs) has been reported in a few small series.

Conference:

Presenting Author: Libre M

Authors: Libre M, Skotte E, Linden A, Wu J, Lippincott E,

Keywords: DIPNECH, somatostatin analogue,

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4645 Radio-guided surgery in use for treatment of early relapse in small intestine neuroendocrine tumours

Introduction: Surgery is the only definitive therapy for neuroendocrine tumours (NET). In number of small intestine NET first symptom is ileus or perforation, lifesaving surgical procedures applied. Such cases have significant risk of recurrence.

Conference:

Presenting Author: Hajac �

Authors: Hajac L, Szewczyk K, Piwkowski P, Chowaniec Z, Mazurak J,

Keywords: radio guided surgery, Neuroendocrine tumour, early relapse,

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,